FLUENT Cannabis Applauds Historic Federal Rescheduling of Cannabis

Core Insights - The rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant policy shift, recognizing its medical use and paving the way for a more regulated national cannabis market [1][2] Group 1: Federal Rescheduling Impact - The Schedule III status will alleviate federal policy barriers, enhance access to banking, and allow companies to deduct ordinary business expenses previously restricted under 280E, thereby freeing up capital for patient care, product innovation, and market expansion [2] - This rescheduling follows a recent federal clarification regarding hemp-derived intoxicants, which is expected to reduce unlicensed competition and alleviate pricing pressures, particularly in key states like Florida and Texas [3] Group 2: Company Commitment and Operations - FLUENT Corp. is dedicated to operational excellence in cultivation, production, distribution, and retail, producing a diverse range of cannabis products under various brands [4] - The company operates in multiple states, including Florida, New York, Pennsylvania, and Texas, employing 700 staff across 8 cultivation and manufacturing facilities and 37 retail locations [4]